Emergency Use of OCR-002 in Acute Liver Failure (ALF)
NCT01634230 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2021-06-24
Summary
This study provides emergency use of the unapproved study medication in ALF patients with acute liver failure who are not responding to standard of care.
Conditions
- Acute Liver Failure
Interventions
- DRUG
-
OCR-002
daily dose: 10 g infused over 24 hours
Sponsors & Collaborators
-
Ocera Therapeutics, Inc.
lead INDUSTRY
Principal Investigators
-
Global Clinical Leader · Ocera Therapeutics
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study of OCE-205 in Participants With Cirrhosis With Ascites Who Developed Hepatorenal Syndrome-Acute Kidney Injury
NCT05309200 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
NCT01041755 ·Status: COMPLETED ·Phase: PHASE4
-
Tolvaptan for Ascites in Cirrhotic Patients
NCT01292304 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
NCT00558038 ·Status: COMPLETED ·Phase: PHASE2
-
Plasma Free Amino Acids in Patients With Hepatic Encephalopathy
NCT03306498 ·Status: UNKNOWN
-
Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding
NCT02158182 ·Status: COMPLETED ·Phase: PHASE4
-
Refractory Ascites in Patients With Liver Cirrhosis, and the Potential Treatment With 48 Hours Infusion of Ularitide.
NCT04311489 ·Status: TERMINATED ·Phase: PHASE2
-
MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
NCT04128462 ·Status: WITHDRAWN ·Phase: PHASE3
-
Unknown Cause of Acute Liver Failure
NCT02041637 ·Status: COMPLETED
-
13C-Methacetin Breath Test for the Prediction of Outcome in in ALI or ALF
NCT02786836 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis
NCT07131969 ·Status: NOT_YET_RECRUITING
-
Multi-national Cirrhosis Study to Characterise the Association Between the Pharmacokinetics of NRL972 and Disease Severity.
NCT00794482 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of L-Ornithine L-Aspartate and Polyethylene Glycol in Cirrhotic Patients With Overt Hepatic Encephalopathy
NCT05920213 ·Status: UNKNOWN ·Phase: PHASE4
-
Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Minimal Encephalopathy
NCT00896831 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of N-Acetylcysteine in Acute Liver Failure (ALF)
NCT00896025 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy of Combined Oral L-ornithine-L-aspartate and Lactulose in Patients With Hepatic Encephalopathy
NCT00740142 ·Status: COMPLETED ·Phase: PHASE4
-
Acetyl-L-Carnitine In Severe Hepatic Encephalopathy
NCT01223768 ·Status: COMPLETED ·Phase: NA
-
PEG3350 in ACLF With Hepatic Encephalopathy
NCT03987893 ·Status: UNKNOWN ·Phase: PHASE4
-
Plasma Exchange in Acute on Chronic Liver Failure
NCT04051437 ·Status: UNKNOWN ·Phase: PHASE3
-
Efficacy of L-ornithine L-aspartate and Therapeutic Plasma Exchange Versus Plasma Exchange Alone in Lowering Ammonia and Improving Outcomes in Pediatric Acute Liver Failure.
NCT05778461 ·Status: UNKNOWN ·Phase: NA
-
Randomized Study of Acetylcysteine in Patients With Acute Liver Failure Not Caused by Acetaminophen
NCT00004467 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
NCT03451292 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Albumin for Acute Encephalopathy in Patients With Cirrhosis
NCT00886925 ·Status: COMPLETED ·Phase: PHASE4
-
Intravenous BCAA for HE in ACLF (BCAA-HE-ACLF)
NCT05700695 ·Status: COMPLETED ·Phase: PHASE1
-
To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase
NCT02788240 ·Status: TERMINATED ·Phase: NA